BR112021025676A2 - Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella - Google Patents
Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotellaInfo
- Publication number
- BR112021025676A2 BR112021025676A2 BR112021025676A BR112021025676A BR112021025676A2 BR 112021025676 A2 BR112021025676 A2 BR 112021025676A2 BR 112021025676 A BR112021025676 A BR 112021025676A BR 112021025676 A BR112021025676 A BR 112021025676A BR 112021025676 A2 BR112021025676 A2 BR 112021025676A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- prevotella
- methods
- mediated condition
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella. a presente invenção refere-se a composições e métodos relacionados a bactérias prevotella que podem ser úteis como agentes terapêuticos, por exemplo, para o tratamento de uma afecção mediada por th2, tal como dermatite atópica e/ou uma alergia alimentar.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962864886P | 2019-06-21 | 2019-06-21 | |
US201962910920P | 2019-10-04 | 2019-10-04 | |
PCT/US2020/038335 WO2020257390A1 (en) | 2019-06-21 | 2020-06-18 | Compositions and methods of treating a th2-mediated condition using prevotella |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021025676A2 true BR112021025676A2 (pt) | 2022-05-17 |
Family
ID=71950833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025676A BR112021025676A2 (pt) | 2019-06-21 | 2020-06-18 | Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3986431A1 (pt) |
JP (1) | JP2022536861A (pt) |
KR (1) | KR20220024684A (pt) |
CN (1) | CN114245742A (pt) |
AU (1) | AU2020297498A1 (pt) |
BR (1) | BR112021025676A2 (pt) |
CA (1) | CA3143994A1 (pt) |
CO (1) | CO2022000278A2 (pt) |
MX (1) | MX2021016034A (pt) |
TW (1) | TW202120109A (pt) |
WO (1) | WO2020257390A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022061141A1 (en) * | 2020-09-21 | 2022-03-24 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2022061119A1 (en) * | 2020-09-21 | 2022-03-24 | Evelo Biosciences, Inc. | Compositions and methods for modulating immune responses with prevotella histicola |
EP4284400A1 (en) * | 2021-01-26 | 2023-12-06 | Evelo Biosciences, Inc. | Prevotella extracellular vesicle preparations |
EP4297762A1 (en) * | 2021-02-26 | 2024-01-03 | Evelo Biosciences, Inc. | Compositions and methods for reducing cytokine expression |
WO2022187064A1 (en) * | 2021-03-01 | 2022-09-09 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
CN113509494A (zh) * | 2021-09-06 | 2021-10-19 | 南京医科大学 | 普氏菌在制备治疗胆汁淤积性疾病的药物中的应用 |
CN114028503A (zh) * | 2021-12-08 | 2022-02-11 | 刘斌 | 治疗过敏性鼻炎的中西药配方及应用 |
WO2023146843A1 (en) * | 2022-01-25 | 2023-08-03 | Evelo Biosciences, Inc. | Extracellular vesicle compositions and methods of use |
WO2023200837A1 (en) * | 2022-04-13 | 2023-10-19 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2023239728A1 (en) * | 2022-06-07 | 2023-12-14 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles |
CN115364223A (zh) * | 2022-08-17 | 2022-11-22 | 郑州可尔利尔生物科技有限公司 | 作用于stat 6靶点的物质成分在制备治疗慢性瘙痒症的药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180093903A (ko) * | 2015-11-03 | 2018-08-22 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 음식 알레르기의 치료 및/또는 예방을 위한 치료용 미생물총 |
GB2557823A (en) * | 2016-03-04 | 2018-06-27 | Univ California | Microbial consortium and uses thereof |
BR112020004347A2 (pt) * | 2017-09-08 | 2020-09-08 | Evelo Biosciences, Inc. | vesículas extracelulares de prevotella |
-
2020
- 2020-06-18 BR BR112021025676A patent/BR112021025676A2/pt not_active Application Discontinuation
- 2020-06-18 MX MX2021016034A patent/MX2021016034A/es unknown
- 2020-06-18 WO PCT/US2020/038335 patent/WO2020257390A1/en active Application Filing
- 2020-06-18 JP JP2021576056A patent/JP2022536861A/ja active Pending
- 2020-06-18 CA CA3143994A patent/CA3143994A1/en active Pending
- 2020-06-18 EP EP20751824.2A patent/EP3986431A1/en active Pending
- 2020-06-18 KR KR1020227001762A patent/KR20220024684A/ko unknown
- 2020-06-18 CN CN202080045114.1A patent/CN114245742A/zh active Pending
- 2020-06-18 AU AU2020297498A patent/AU2020297498A1/en not_active Abandoned
- 2020-06-20 TW TW109121018A patent/TW202120109A/zh unknown
-
2022
- 2022-01-17 CO CONC2022/0000278A patent/CO2022000278A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022000278A2 (es) | 2022-01-28 |
JP2022536861A (ja) | 2022-08-19 |
WO2020257390A1 (en) | 2020-12-24 |
TW202120109A (zh) | 2021-06-01 |
CA3143994A1 (en) | 2020-12-24 |
MX2021016034A (es) | 2022-02-21 |
EP3986431A1 (en) | 2022-04-27 |
CN114245742A (zh) | 2022-03-25 |
AU2020297498A1 (en) | 2022-01-20 |
KR20220024684A (ko) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021025676A2 (pt) | Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella | |
BR112022002150A2 (pt) | Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola | |
EA202091389A1 (ru) | Композиция на основе пробиотиков и её применение | |
CL2018001349A1 (es) | Composiciones que comprenden cepas bacterianas | |
CL2018001367A1 (es) | Composiciones que comprenden cepas bacterianas | |
BR112018015097A2 (pt) | composição e reatores | |
DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
BR112018069220A2 (pt) | uso de polipeptídeo que tem atividade de dnase para tratamento de tecidos | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
CO2017013443A2 (es) | Composiciones que comprenden cepas bacterianas del género blautia | |
NZ730865A (en) | Peptides having anti-inflammatory properties | |
EP4219713A3 (en) | Products and compositions | |
BR112018067689A2 (pt) | composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral | |
CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
BR112018068593A2 (pt) | composições tópicas não aquosas que compreendem uma salicilanilida halogenada | |
NZ759766A (en) | Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety | |
EP4299129A3 (en) | Dosing regimen for treatment of cognitive impairments with blood plasma products | |
BR112017010808A2 (pt) | prevenção e tratamento de infecções microbianas | |
EA201990257A1 (ru) | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением | |
BR112019003172A2 (pt) | frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento | |
CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
CO2017001025A2 (es) | Métodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la pérdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
MX2017002673A (es) | Reutilizacion de agente cloroso activado para el tratamiento de carne y aves. | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |